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ARTICLE
HypoxamiR-210 accelerates wound healing in
diabetic mice by improving cellular metabolism
Sampath Narayanan1,2, Sofie Eliasson Angelstig1,2, Cheng Xu1,2, Jacob Grünler1,2, Allan Zhao1, Wan Zhu3,
Ning Xu Landén 4, Mona Ståhle4, Jingping Zhang5, Mircea Ivan 6, Raluca Georgiana Maltesen 7,
Ileana Ruxandra Botusan1,2, Neda Rajamand Ekberg1,2, Xiaowei Zheng 1,2,9✉ &
Sergiu-Bogdan Catrina 1,2,8,9✉
Wound healing is a high energy demanding process that needs a good coordination of the
mitochondria with glycolysis in the characteristic highly hypoxic environment. In diabetes,
hyperglycemia impairs the adaptive responses to hypoxia with profound negative effects on
different cellular compartments of wound healing. miR-210 is a hypoxia-induced microRNA
that regulates cellular metabolism and processes important for wound healing. Here, we
show that hyperglycemia blunted the hypoxia-dependent induction of miR-210 both in vitro
and in human and mouse diabetic wounds. The impaired regulation of miR-210 in diabetic
wounds is pathogenic, since local miR-210 administration accelerated wound healing speci-
fically in diabetic but not in non-diabetic mice. miR-210 reconstitution restores the metabolic
balance in diabetic wounds by reducing oxygen consumption rate and ROS production and by
activating glycolysis with positive consequences on cellular migration. In conclusion, miR-210
accelerates wound healing specifically in diabetes through improvement of the cellular
metabolism.
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Wound healing is a complex process with high energydemands that involves several cellular compartmentsincluding keratinocytes, fibroblasts, endothelial and
immune cells. The high energy needs are metabolically challen-
ging since the wound environment is highly hypoxic due to
reduced oxygen supply secondary to loss of vascularization.
Wound healing is impaired in diabetes, and diabetic foot ulcer
(DFU) represents a devastating complication of diabetes with
drastic consequences for patients and society. The energy balance
in diabetic wounds is even more difficult to achieve since hypoxia
is more profound than in normoglycemic wounds1 and the cel-
lular reactions to hypoxia are impaired in diabetes2 due to
repressed hypoxia inducible factor-1 (HIF-1) signaling3. Local
pharmacological reversal of the repressed HIF-1 signaling in
diabetes is followed by the promotion of wound healing sec-
ondary to the improvement of several energy-demanding pro-
cesses i.e. angiogenesis, dermal and epidermal regeneration1,4.
HIF-1 is a master regulator of oxygen homeostasis and there-
fore drives a large number of cellular processes. Currently,
approximately 1000 human genes are identified to be directly
influenced by HIF-1, which binds to the functionally cis-acting
regulatory element called hypoxia response element (HRE)5.
MiR-210 is a unique microRNA that possesses an HRE and it is
exclusively regulated in hypoxia by HIF-1 signaling6 and it
is modulated in a dose-dependent manner by oxygen7. miR-210
is ubiquitously expressed and influences the expression of a
cluster of genes that are involved in processes highly relevant for
energy metabolism and for tissue regeneration including angio-
genesis, cell proliferation/apoptosis, and metabolic adaptation8. It
has previously been shown that miR-210 has higher expression
levels at the edge of ischemic wounds and inhibits keratinocyte
proliferation9, and that anti-miR-210 treatment could accelerate
healing of ischemic wounds10. However, to our knowledge, the
regulation and function of miR-210 in diabetic wound has not
been investigated before.
In this study, we investigated the contribution of miR-210 for
the hypoxia signature in wound healing in diabetes. We show that
the induction of miR-210 is repressed in the wounds of diabetic
patients and in experimental wounds of diabetic db/db mice.
Local reconstitution of miR-210 improved wound healing speci-
fically in db/db mice by restoring metabolic balance and
improving processes central to wound healing.
Results
High glucose levels inhibit the induction of miR-210 expres-
sion in hypoxia. We first investigated the modulation of miR-210
expression by hypoxia in human dermal fibroblasts (HDF),
human dermal microvascular endothelial cells (HDMEC), and
keratinocytes, which are the most functionally relevant cellular
components of the skin. As expected, hypoxia induced miR-210
expression in a time-dependent manner in all the three cell types
(Fig. 1a–c). High glucose concentrations, however, diminished
the hypoxia-induced expression of miR-210 in these cells
(Fig. 1d–f).
miR-210 expression is inhibited in diabetic wounds. In
response to the hypoxic environment, wound miR-210 expression
was increased compared with that of skin in normoglycemic
mice, as shown by both in situ hybridization (Fig. 2a) and
quantitative RT-PCR analysis (Fig. 2b). The db/db mouse model
is a widely validated model for investigating the impaired
mechanisms of wound healing in diabetes11, in which the hypoxic
environment was confirmed1 exactly as in humans3. Although
wounds of db/db diabetic mice are more hypoxic than those of
normoglycemic mice1, miR-210 expression was significantly
lower in the wounds of db/db mice (Fig. 2a, b). These repressed
levels of miR-210 reflect the impaired HIF-1 signaling in diabetic
wounds1 since they could be reversed when HIF-1 signaling was
restored by local treatment with Dimethyloxalylglycine (DMOG)
known to be able to overcome the repressing effect of diabetes
on HIF-1 signaling2 (Fig. 2e, f). Moreover, miR-210 expression
was reduced in DFU compared to age-matched nondiabetic
venous ulcer (VU) subjects (Fig. 2c, d). Taken together, these
results suggest that reduced miR-210 expression may contribute
to the impaired wound healing in diabetes.
Local reconstitution of miR-210 in the wounds improves
wound healing specifically in diabetes. In order to examine the
pathophysiological relevance of the impaired induction of miR-
210 during wound healing in diabetes, we investigated the effects
of locally injected miR-210 mimic, a stabilized form of miR-210,
on wound healing rate of db/db mice. miR-210 reconstitution
promoted wound healing in db/db mice (Fig. 3a–c) despite per-
sistent profound hyperglycemia (Supplementary Fig. 1a, b). The
positive effect of miR-210 on wound healing was driven locally
since practically no systemic distribution was detected (Supple-
mentary Fig. 1c). Interestingly, miR-210 improved the wound-
healing rate specifically in diabetic mice, with no effect on the
wound-healing rate in nondiabetic mice (Fig. 3d, e).
The histological examination of the wounds revealed that miR-
210 improved several cellular processes essential for wound
healing. The overall increase in the granulation tissue (Fig. 3f)
followed an increase in the cellular proliferation rate as evaluated
by ki67 (Fig. 3i) and angiogenesis as evaluated by CD31
immunostainings (Fig. 3h), which were characteristically
impaired during wound healing in diabetes. miR-210 also
increased collagen deposition in the granulation tissue of diabetic
wounds as assessed by the Masson–Goldner Trichrome staining
(Fig. 3g). The prolonged inflammatory phase characteristic of
diabetic wounds, denoted by an elevation in the CD11b
expression, was also normalized by miR-210 reconstitution
(Fig. 3j).
miR-210 restores metabolic balance in diabetic wounds. Taking
into account the aforementioned effects of miR-210 on cellular
processes that require high energy and the known effect of miR-
210 on the energy metabolism12, we decided to explore the role of
miR-210 on the cellular metabolism during wound healing.
Indeed, among the five validated potential mitochondrial target
genes of miR-21013, local administration of miR-210 repressed
the expression of two genes that are central for mitochondrial
function, namely Iron-sulfur cluster assembly enzyme (ISCU) and
D-subunit of Succinate dehydrogenase (SDHD) (Fig. 4a).
In agreement with its effects on these mitochondrial target
genes, the administration of miR-210 had a profound influence
on mitochondrial respiration by reversing the increased oxygen
consumption rate (OCR) in db/db wounds to the levels found in
the wounds from control nondiabetic mice (Fig. 4b). Interest-
ingly, miR-210 reconstitution also led to an increase in the
production of lactate (Fig. 4c), denoting an increase in glycolysis.
Although this metabolic reprograming did not result in a net
increase in the ATP production (Supplementary Fig. 2), it
contributed to reduced ROS levels in db/db wounds after local
miR-210 mimic administration (Fig. 4d).
Metabolic reprogramming by miR-210 improves fibroblast
function. Since the bulk of the granulation tissue consists of
fibroblasts, it was of interest to study the effects of miR-210 in
these cells in diabetic setting. In accordance with the findings in
db/db wounds, miR-210 mimic transfection in HDFs exposed to
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hypoxia and high glucose concentrations led to a significant
decrease in the mRNA levels of ISCU and SDHD (Fig. 5a and
Supplementary Fig. 3a). Moreover, miR-210 reconstitution
decreased OCR (Fig. 5b), enhanced glycolysis (Fig. 5c) and
diminished ROS levels (Fig. 5d) in HDFs exposed to hypoxia and
high glucose levels. The metabolic changes induced by miR-210
reconstitution was further validated by the real-time ATP
synthesis rate assay on a Seahorse XF analyzer. As shown in
Fig. 5e, a significantly smaller proportion of ATP was generated
via mitochondria respiration and a higher proportion of ATP was
generated by glycolysis after miR-210 reconstitution in HDFs that
were exposed to high glucose levels in hypoxia. We have
further investigated the functional implications of the miR-210-
induced metabolic reprogramming by evaluating the migration of
HDF. The miR-210-induced migration of HDF exposed to high
glucose levels in hypoxia was abrogated when glycolysis was
inhibited in different ways by, namely, 2-deoxy-D-glucose (2-DG),
syrosingopine and sodium oxamate in HDFs (Fig. 5f and Sup-
plementary Fig. 3b). This suggests that the positive effect of miR-
210 on HDF migration is mediated by an increase in glycolysis.
Taken together, these results indicate that miR-210 could
reprogram the cellular energy metabolism which in turn improves
the cellular function under diabetic conditions.
Discussion
The high cellular energy demands during wound healing depends
on an appropriate metabolic shift to cope with the low oxygen
levels14. A pivotal role for the adequate reaction to hypoxia and
for wound-healing processes is played by HIF-1 signaling that is
responsible for the adaptation of metabolism, cellular motility
and proliferation, immune response and angiogenesis15. DFU are
however characterized by a repressed HIF-1 activation with direct
negative consequences for wound healing3. Reactivation of HIF-1
Fig. 1 High glucose levels inhibit miR-210 induction at hypoxia. a–c miR-210 expression in human dermal fibroblasts (HDF) (n= 5), human dermal
microvascular endothelial cells (HDMEC) (n= 9), and keratinocytes (n= 9) that were exposed to normoxia (N) or hypoxia for 6 h (H6) and 24 h (H24).
*P < 0.05 compared with N. d–f The cells were cultured in normal (5.5 mM) or high (30mM) glucose (Glu) levels for 24 h and exposed to normoxia (N) or
hypoxia (H) for 24 h (d) and 6 h (e, f) respectively. Relative miR-210 levels are shown. Statistical differences were calculated by one-way ANOVA. Data are
represented as mean ± s.e.m. *P < 0.05.
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Fig. 2 Reduced miR-210 expression in diabetic wounds. a, b miR-210 expression levels were analyzed in skin (n= 10) and wounds (n= 9) from
normoglycemic wild-type (WT) mice, as well as in wounds from db/db diabetic mice (n= 10) using in situ hybridization (a) and quantitative RT-PCR (b).
c, dWound biopsies from diabetic foot ulcers (DFU, n= 8) and venous ulcers (VU, n= 7) were analyzed for miR-210 expression using in situ hybridization
(c) and quantitative RT-PCR (d). Scale bar= 50 μm. HIF-1α expression was analyzed by immunofluorescence (e) and miR-210 expression levels by
quantitative RT-PCR (f) in wounds from WT-control mice (n= 8) and wounds from db/db mice treated with placebo (n= 4) or with DMOG (n= 4).
Scale bar= 100 μm. Statistical differences were calculated using one-way ANOVA (b, f) and Student’s t test (d). Data are represented as mean ± s.e.m.
*P < 0.05.
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signaling in diabetic wounds is sufficient to reverse the wound-
healing potential1. A clinical study that addresses the effects of
activation of the HIF-1 signaling in DFU is ongoing (Clin-
icalTrials.gov Identifier: NCT03137966). The targets of HIF-1
signaling is however broad and modulate several cellular path-
ways that might not be involved in wound-healing process. It is
therefore of value to explore a narrower relevant hypoxic sig-
nature for just the processes important for wound healing. Here
we show that miR-210, which directly regulates approximately 30
genes13, is sufficient to improve the impaired wound healing
specifically in diabetes.
The induction of miR-210 by hypoxia is in perfect agreement
with its exclusive regulation by HIF-1 signaling and its ubiquitous
expression6,7. The central regulatory role of HIF-1 for miR-210
function explains the repressive effect of hyperglycemia on miR-
210 induction in hypoxia observed in cells and in vivo, which
mirrors the well-documented glucose-dependent suppression of
HIF-1 signaling in hypoxia16. Low expression of miR-210 has
been reported in the pancreatic islets of diabetic animals and
contributes to beta cell death17. On the other hand, high levels of
miR-210 were reported in the serum and urine of patients
with newly diagnosed Type 1 Diabetes18–20, and the hearts of
Fig. 3 Local miR-210 administration improves wound healing specifically in diabetes. Full-thickness excisional wounds were made on the dorsum of db/
db and WT control mice, and control mimic (Ctrl) or miR-210 mimic (miR-210) was injected intradermally in the wound edge on day 0 and day 6. Wounds
were harvested on day 8. a, dmiR-210 expression in wounds analyzed by quantitative RT-PCR (n= 6, 7, 8, 5 for WT-Ctrl, WT-miR-210, db/db-Ctrl and db/
db-miR-210 groups, respectively). b, e Wound images were obtained every alternate days and wound healing rate is shown as the percentage of the initial
wound area (n= 10, 11, 12, 14 for WT-Ctrl, WT-miR-210, db/db-Ctrl and db/db-miR-210 groups, respectively). c Representative wound images during the
healing process. f–j Levels of granulation, collagen deposition, proliferation, angiogenesis and inflammation were evaluated by histological analysis of H&E
staining (f n= 4, 6 and 6 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively), Masson−Goldner Trichrome staining (g n= 8, 9 and 9 for
WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively), CD31 (h n= 4, 5 and 5 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively),
Ki67 (i n= 4, 4 and 3 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively), and CD11b staining (j n= 3, 5 and 4 for WT-Ctrl, db/db-Ctrl and
db/db-miR-210 groups, respectively). Results of semiquantitative evaluations are presented in the histograms. Statistical differences were calculated using
Student’s t test (a, d), two-way ANOVA (b, e) and one-way ANOVA (f–j), respectively. Data are represented as mean ± s.e.m. *P < 0.05.
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diabetic rats21, but the levels were not corrected for tissue
oxygen tensions that are generally lower in diabetic tissues16,22.
Similar to HIF-1α expression, the miR-210 expression in diabetic
tissues is dependent on the balance between the induction by
hypoxia and the inhibition by high glucose levels. It is not sur-
prising to detect higher miR-210 levels in diabetic tissues
since they are more hypoxic than the corresponding controls
which are not hypoxic. The inhibitory effects of high glucose
concentrations will be unveiled when comparing hypoxic
conditions with similar oxygen tensions or after correction
for tissue oxygen concentrations. Our results showed that miR-
210 expression increased in response to hypoxia in control
wounds but was inhibited by hyperglycemia in diabetic wounds
despite a more profound hypoxia1. This is confirmed by the fact
that miR-210 increases to normal levels when impaired HIF-1
signaling in diabetes is rescued by the local treatment with
DMOG. This confirms the insufficient adaptive response to
hypoxia in diabetic wounds, which contributes to impaired
wound healing.
The characteristically glucose-dependent impairment of cellular
functions central for wound healing such as repressed proliferation,
migration, and angiogenesis and increased inflammation were at
least partially attributable to the decreased miR-210 expression in
diabetic wound since its reconstitution restored them. miR-210
reconstitution improved granulation, proliferation and angiogenesis
in the same way as the induction of HIF-1 signaling does in diabetic
wounds1. The positive effect of miR-210 on angiogenesis is in
agreement with previous reports showing miR-210 modulates
endothelial cell response23 and promotes angiogenesis in ischemic
tissues24,25. The stimulatory effects of miR-210 on cell proliferation
and migration are in line with previous observations in normal or
transformed cells23,26–28. However, this effect seems to be depen-
dent on cellular context and on oxygen levels9,29.
The reconstitution of miR-210 in the wounds of diabetic mice
was sufficient to improve healing despite persistent hyperglyce-
mia. It is highly specific for diabetic condition probably because
of the disease-dependent inhibition of miR-210 during diabetic
wound healing but it has no effect when it is expressed at suffi-
cient levels during normal wound healing. Extremely high
expression of miR-210 can even have a retarding effect on wound
healing since it mimics profound ischemic conditions that are
notorious for their deleterious effects on tissue regeneration9. It is
interesting that inhibition of miR-210 was also followed by
improvement in wound-healing rate in a model of impaired
healing in diabetes30 The apparently opposing effects of miR-210
might be due to the differences in pharmacokinetics and wound
models but might also mirror the fact that the biological effects of
the hypoxamiR-210 are a mixture between its direct effects and
the indirect effects played through HIF-1, which might be dif-
ferently modulated by different pharmacological approaches.
The beneficial effects of miR-210 on the improvement of
wound healing in diabetes can be at least partially explained by its
effects on energy metabolism. The OCR of diabetic wounds was
highly increased compared with nondiabetic wounds, which is in
accordance with other reports on diabetic tissues31,32. Increased
oxygen consumption results in hypoxia in diabetes in general22,
and especially in diabetes wounds1 due to the mismatch with
oxygen delivery. It might well activate a vicious circle since the
central mechanism for the adaptive responses to hypoxia, HIF-1
signaling, is repressed in diabetes16. Our data demonstrate that
miR-210 diminished OCR in diabetic wounds as well as in HDFs
exposed to high glucose concentrations in hypoxia. miR-210
could achieve this by downregulating ISCU, which is required for
the formation of iron-sulfur cluster that is present in various
enzymes of the tricarboxylic acid (TCA) cycle. miR-210 also
reduced the expression levels of SDHD, an enzyme that takes part
Fig. 4 miR-210 restores metabolic balance in diabetic wounds. a Gene expression of mitochondrial targets of miR-210—ISCU, SDHD, ALDH5A, NDUFA4
and COX10 were analyzed from control mimic or miR-210 mimic injected db/db wounds (n= 7–10). b Oxygen consumption rate was analyzed from freshly
harvested wounds using Seahorse XF Analyzer (n= 5, 6 and 6 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively). c Lactate levels were
detected from tissue lysates (n= 9, 6 and 7 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups, respectively). d ROS levels were measured by detecting
the amount of 4-HNE in the control mimic or miR-210 mimic injected wounds (n= 5, 11 and 9 for WT-Ctrl, db/db-Ctrl and db/db-miR-210 groups,
respectively). Statistical differences were calculated by one-way ANOVA. Data are represented as mean ± s.e.m. *P < 0.05.
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in both TCA cycle and the electron transport chain (ETC) in the
mitochondria. Moreover, miR-210 could enhance glycolysis that
was inhibited in diabetic compared with nondiabetic control
wounds. ROS levels were diminished by miR-210 as a con-
sequence of the restoration of the balance between mitochondrial
respiration and glycolysis. The enhanced glycolysis mediated the
positive effects of miR-210 on the migration of HDF that were
exposed to high glucose levels in hypoxia. This is in perfect
agreement with the emerging role of glycolysis in promoting
angiogenesis33 and other cellular processes involved in tissue
repair and regeneration34,35.
In conclusion, our results demonstrate a metabolic change in
diabetic wounds characterized by increased OCR and ROS levels
and decreased glycolysis due to inhibited miR-210 expression by
hyperglycemia. miR-210 reconstitution can reverse the metabolic
changes by inhibiting OCR and enhancing glycolysis and con-
sequently normalize ROS levels and promote wound healing
specifically in diabetes (Fig. 6). These data suggest that local miR-
210 administration in diabetic wounds is a promising therapeutic
approach for DFU.
Methods
Chemicals. Custom-stabilized miRIDIAN mmu-microRNA-210-3p mimic
(C-310570-5) and custom-stabilized miRIDIAN negative control mimic #1 (CN-
001000-01) were obtained from Dharmacon. MaxSuppressorTM In Vivo RNA-
LANCEr II was from BIOO Scientific, RNAlaterTM Stabilization solution were
obtained from ThermoFisher Scientific, 10% neutral buffered formalin solution
from Sigma, and Mayers Hemotoxylin and 0.2% Eosin from Histolab. Mmu-miR-
210-3p-specific LNA-probes were obtained from Exiqon. 2-deoxy-D-Glucose,
Syrosingopine and sodium oxamate were purchased from Sigma Aldrich.
Human wound biopsies. Eight patients with DFU (age: 69.1 ± 9.9 years old;
HbA1c: 59.71 ± 11.52 mmol/mol) and seven patients with venous ulcer (age: 78.4 ±
6.9 years old) were recruited after agreeing and providing their informed consent.
Detailed information of these subjects is given in Table 1. The Regional Ethical
Review Board in Stockholm, Sweden approved the study. The wound biopsies were
taken using 4 mm biopsy punch after local anesthesia.
Animals. BKS(D)-Leprdb/JOrIRj (db/db) mice and their corresponding normo-
glycemic wild-type (WT) control mice were obtained from Janvier Labs. The mice
were housed up to five per cage in a 12-h light/dark cycle at 22 °C and were
provided standard laboratory food and water ad libitum. The animals were caged
individually and handled daily for 1 week before wounding. The mice were ran-
domized into groups receiving control microRNA mimic or miR-210 mimic
according to their HbA1c levels, body weight and blood glucose levels. The sample
size was determined using power calculations based on the results from the same
mouse model in our previous studies1,36.
Wound model. The wound model was created as described previously1. Following
blood glucose control, the mice were anesthetized and the hair from the back were
removed using a shaver followed by a depilatory cream. The skin was cleaned with
70% ethanol and two full-thickness wounds extending through the panniculus
carnosus were created on either side of the dorsal midline using a 6-mm biopsy
punch. MiR-210 mimic (0.125 nmol) or negative control mimic were injected
intradermally at four different places in the wound edges on the day of wounding
as well as after 6 days post surgery. In wound experiment using DMOG, 100 μL
DMOG (2 mM) or vehicle were applied locally every other day. Digital photo-
graphs were obtained on the day of wounding and every other day after wounding.
A circular reference of known area was placed alongside the wounds to allow for
correction of the distance between the camera and the wound. The wound area was
Fig. 5 Metabolic reprogramming by miR-210 improves fibroblasts function. HDF cells were transfected with control mimic or miR-210 mimic and
exposed to hypoxia and high glucose concentration (30mM) followed by measurement of a gene expression levels of ISCU (n= 6) and SDHD (n= 5),
b oxygen consumption rate (OCR) (n= 6), c extracellular acidification rate (ECAR) (n= 4), d ROS levels (n= 5) and e mitochondrial and glycolytic ATP
production rate (n= 5). f Migration of HDF that were treated with vehicle or glycolysis inhibitors 2-deoxy-D-Glucose (2-DG, 15 mM), Syrosingopine (Syro,
10 µM), and Oxamate (45mM) along with hypoxia and high glucose concentrations (n= 6). Statistical differences were calculated using paired Student’s t
test. Wilcoxon matched-pairs signed rank test was used for Syrosingopine-treated groups where the data were not normally distributed. Data are
represented as mean ± s.e.m. *P < 0.05.
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calculated using ImageJ software, version 1.47 (NIH, USA), corrected for the area
of the reference circle and expressed as percentage of the original area. The data
analysis was blinded. On day 8 after wounding, the animals were euthanized and
the wounds were harvested. One part of the wounds was snap frozen, one part was
placed in RNALater and the rest used for Seahorse analysis. One half of the other
wound was placed in 10% formalin to be processed for histology and staining.
Histology. Histology was performed on formalin-fixed, paraffin-embedded sec-
tions (5 µm). The slides were stained with hematoxylin and eosin after depar-
affinization and rehydration. Subsequently, the granulation area of the wound was
quantified. Image analysis and quantification was done using smart segmentation
feature on Image Pro Premier software, version 9.2 (Media Cybernetics). At least
two images from each slide were evaluated and each condition had 4–6 slides.
Granulation was measured as ratio of the number of cells to the total area of the
granulation layer in an image.
Fluorescent immunohistochemistry. Formalin-fixed, paraffin-embedded tissues
(FFPE) were deparaffinized and rehydrated. Antigen retrieval was performed in a
microwave (800W for 10 min) using citrate buffer. Slides were then washed with
PBS-T (Phosphate buffered saline supplemented with 0.1% Tween) 3 times for
3 min each. The sections were blocked with goat serum or 5% bovine serum
albumin (BSA) in PBS for 30 min at RT, then incubated with primary antibodies
overnight at 4 °C. After three times wash with PBS-T for 3 min each, the sections
were incubated with fluorochrome-conjugated secondary antibody for 1 h at RT in
dark. The sections were washed in PBS-T three times for 3 min each and treated
with 0.1% Sudan Black-B solution (Sigma) for 10 min to quench autofluorescence.
After washing, the sections were incubated with 1:5000 diluted DAPI (4′,6-dia-
midino-2-phenylindole, Thermo-Fisher Scientific) in PBS for 5 min and followed
by washing in PBS-T for 5 min. The sections were then mounted and stored in
4 °C. The fluorescent images were acquired using Leica TCS SP5 or SP8 confocal
microscope (Leica Microsystems).
To detect HIF-1α, the fluorescent signal was enhanced using Tyramide
Superboost kit (Thermofisher). Briefly, following antigen retrieval, the sections
were blocked with 3% H2O2 before blocking with goat serum. The sections were
incubated with primary antibody and washed with PBS-T 5min four times
followed by incubation with an HRP-conjugated rabbit antibody for 1 h at RT. The
sections were washed thoroughly and incubated with tyramide reagent for 10 min
at RT in dark. The reaction was stopped by incubating with the stop solution for
5 min and three times washed with PBS-T for 3 min each. The sections were
subsequently treated with 0.1% Sudan Black-B solution, followed by
counterstaining with DAPI (1:5000) for 5 min. The sections were finally washed
with PBS-T and mounted.
Image analysis was performed using Image-Pro Premier, version 9.2 (Media
Cybernetics) and ImageJ software, version 1.47 (NIH, USA). For CD31, Ki67 and
CD11b staining, 2–5 images per tissue and a total of at least three tissues per
condition were considered for image analysis. The total number of nuclei and cells
with positive signal were counted. Quantification for each staining is expressed as
percentage of positive cells to total number of cells. The following primary
antibodies were used: anti-CD31 from Dianova (DIA310, 1:100); anti-Ki67 from
Abcam (ab15580, 1:1000), anti-CD11b from Merck Millipore (MABF512, 1:100)
and anti-HIF-1α (GTX127309, 1:100). The secondary antibodies used were goat
anti-rat Alexa Fluor 488 (A11006, 1:500) and goat anti-rabbit Alexa Fluor 488
(A11008, 1:500) from ThermoFisher Scientific.
In situ hybridization. For the detection of miR-210 in FFPE sections, Exiqon
miRCURY locked nucleic acid (LNA)-DIG labeled probe was used as previously
described37 with some modifications. Briefly, FFPE slides (5 μm thickness) were
deparaffinized and the RNAs were demasked by 15 μg/mL proteinase K treatment
for 10 min at 37 °C. The probes were hybridized with Mmu-miR-210-3p-specific
LNA-probes (Exiqon) at a concentration of 250 nM for 2 h at 53 °C. Stringent
washes were carried out at 53 °C with decreasing concentrations of Saline-Sodium
Citrate buffer (SSC) (once in 5× SSC, twice in 1× SSC and twice in 0.2× SSC) for
5 min followed by a final wash with 0.2× SSC at room temperature. The sections
were then blocked and incubated with an alkaline phosphatase (AP)-conjugated
antibody specific to DIG (Roche, 1:1000) for 1 h at room temperature. The signal
for miR-210 was visualized by addition of an AP substrate, NBT/BCIP (Thermo-
Fisher) and the slides were counterstained with nuclear fast red stain (Vectorlabs).
Masson−Goldner Trichrome staining. FFPE sections of wounds were depar-
affinized with two passes in Xylene for 3 min each and rehydrated in sequential
passes of 100% and 95% ethanol for 3 min, two times each. The slides were treated
according to the manufacturer’s instructions to obtain Masson−Goldner Tri-
chrome staining (Merck Millipore). Images of the staining were obtained using
Leica DM3000 LED fluorescence microscope using the transmitted light. The
collagen stained areas in the wounds were analyzed and quantified using the Smart
Segmentation feature on Image Pro Premier software, version 9.2 (Media Cyber-
netics). At least 2–4 images from 3 to 4 tissues from each condition were analyzed.
Collagen staining was expressed as the percentage of area stained by collagen
(green).
Fig. 6 Schematic illustration of the cellular metabolic changes in diabetic wounds that can be reversed by miR-210 reconstitution. a In normal hypoxic
wound cell, miR-210 is induced by hypoxia and regulates appropriate responses of mitochondrial oxygen consumption (OCR) and glycolysis. b In diabetic
hypoxic wound cell, miR-210 induction is blunted, resulting in increased OCR, reduced glycolysis, and consequently elevated ROS levels which are
detrimental to wound healing. c In miR-210-reconstituted diabetic hypoxic wound cells, miR-210 can reverse the metabolic changes by inhibiting OCR and
enhancing glycolysis and consequently normalize ROS levels which are beneficial for wound healing.
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4-Hydroxynonenal measurement. 4-Hydroxynonenal (4-HNE) was measured in
frozen wound lysates using commercially available kits (OxiSelect STA-838 and
STA-310, Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s
instructions.
Lactate assay. Lactate production was measured using the Lactate Colorimetric
Assay kit from Biovision according to the manufacturer’s instructions. Wound
tissues were homogenized in lactate assay buffer provided in the kit and lactate
levels were measured and normalized to the protein levels.
Cell culture. Primary HDFs (ATCC, USA) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; 5.5 mM glucose) supplemented with 100 IU/ml penicillin
and streptomycin, and 10% heat-inactivated FBS (fetal bovine serum, Invitrogen).
The cells were maintained in a humidified atmosphere with 5% CO2 at 37 °C in a
cell culture incubator, and passages 4–9 were used for experiments. Cells were
cultured under normoxic [21% O2 (vol/vol)] or hypoxic (1% O2) conditions in
Hypoxia Workstation INVIVO2 (MedicalExpo).
Transfection of miR-210 mimic in HDF. HDFs were transfected with miR-210
mimic or negative control mimic using Lipofectamine RNAiMAX (Life Technol-
ogies) according to the manufacturer’s instructions. The cells were harvested
24–48 h after transfection. Total RNA was extracted and the expression levels of
miR-210 were analyzed.
RNA purification and quantitative RT-PCR. Total RNA, including microRNAs,
was extracted from cells and tissues using a miRNeasy RNA extraction kit (Qia-
gen). To detect mRNA expression, high-capacity cDNA Reverse Transcription Kit
(ThermoFisher Scientific) was used. All quantitative RT-PCR was performed on a
7300 Real-Time PCR System or QuantStudio 6 and 7 Flex Real-Time PCR System
(Applied Biosystems) using SYBR Green Master Mix or Taqman Gene Expression
Assays (ThermoFisher Scientific). The internal controls for mRNA expression were
PBGD and Actin. The primer sequences for SYBR Green quantitative RT-PCR
were: mouse ALDH5A1_F: CCAGTCATCAAGTTTGATAAGGAG; mouse
ALDH5A1_R: GAGCCCTTCATTCACACC; mouse NDUFA4_F: GCATCCCAG
CTTGATTCCT; mouse NDUFA4_R: GTTTGCTGTAGTCCACATTCAC; mouse
ACTB_F: AAGATCAAGATCATTGCTCCTC; mouse ACTB_R: GGACTCA
TCGTACTCCTG; mouse PBGD_F: TCCCTGTTCAGCAAGAAGA; mouse
PBGD_R: GGCAGTGATTCCAACCAG. TaqMan Gene Expression Assays were
Mm02342800_g1 for mouse ISCU; Mm00546511_m1 for mouse SDHD;
Mm00617695_m1 for mouse COX10; Mm01143545_m1 for mouse PBGD; and
Mm02619580_g1 for mouse β-actin.
MicroRNA detection. TaqMan microRNA Reverse Transcription kit and TaqMan
miRNA assays (ThermoFisher Scientific) were used for the analysis of miR-210,
U6 snRNA and snoRNA55 expression (assay IDs were 000512, 001228, and 001973
respectively). U6 was used as internal control for HDF and keratinocytes, and
snoRNA55 was used as control for mouse tissues. To detect miR-210 expression in
HDMEC and human wounds, cDNA was produced using TaqMan Advanced
miRNA cDNA Synthesis Kit (ThermoFisher Scientific) and microRNA expression
was detected using TaqMan Advanced miRNA assays (ThermoFisher Scientific),
where miR-103a or the average of miR-16, miR-23a, and miR-24 were used as
internal controls. The TaqMan Advanced miRNA assays were hsa-miR-210-3p
(477970_mir), hsa-miR-103a-3p (478253_mir), hsa-miR-16-5p (477860_mir), hsa-
miR-23a-3p (478532_mir), and hsa-miR-24-3p (477992_mir).
In vitro migration assay. HDF migration was studied using the scratch assay. Cells
were plated in 24-well plates coated with collagen (50 µg/µL) overnight and blocked
with 3% BSA in PBS for 2 h. At 90% confluency, the cells were transfected with the
miR-210 mimic or negative control mimic as mentioned above. At 24 h after trans-
fection, a scratch was generated in each well with a micropipette tip. The cells were
rinsed and treated with normal (5.5mM) or high glucose (30mM) medium sup-
plemented with 0.2% FBS and the plates were placed in normoxia or hypoxia.
Mitomycin C (10 µg/mL) (Roche) was included in the media to prevent cell pro-
liferation. Digital pictures were obtained immediately after scratching and after 16 h
using EVOS XL Core Cell Imaging System (ThermoFisher Scientific). Images were
analyzed using ImageJ, version 1.47 software (NIH, Bethesda, MD, USA). The
experiment was done in triplicates and three images from each replicate were used for
analysis. On each image, the distance between the two sides of the scratch was
measured at certain intervals using ImageJ and the mean of distance was
calculated. Migration rate was calculated as the difference between the mean of
distance at 0 h (Distance_0h) and 16 h (Distance_16h) divided by the distance at 0 h
((Distance_0h−Distance_16h)/Distance_0h). The migration rate for each condition
was expressed as percentage to the control condition and was expressed as Relative
Migration.
Measurement of oxygen consumption, extracellular acidification, and ATP
production rates. Basal OCR, extracellular acidification rate (ECAR), and ATP
production rate were measured using XF Cell Mito Stress Test kit, XF Glycolytic
Rate Assay kit, and XF Real-Time ATP Rate Assay kit on Seahorse XF Analyzer
(Agilent Technologies). The sensor cartridges used for measuring the oxygen flux
was equilibrated in an XF Calibrant (Agilent Technologies) for 16–24 h before the
experiment in a 0%-CO2 37 °C incubator. The granulation tissue from the wounds
taken from mice after 8 days of wounding was carefully dissected and rinsed with
unbuffered Krebs-Henseleit buffer (KHB) media. The tissue was placed at the
bottom of the XF24 Islet Capture Microplate (Agilent technologies) and covered
with a mesh. Four hundred and fifty microliters KHB medium was added to each
well containing the tissue and equilibrated in a 0%-CO2 incubator for 30 min. The
cartridge was then placed on the assay plate and run in the XF analyzer using an
optimized protocol to measure basal OCR. For analysis in cells, HDFs were
transfected with negative control mimic or miR-210 mimic and treated with
normal (5.5 mM) or high (30 mM) glucose levels in normoxia or hypoxia. The cells
from each condition were then seeded onto an XF24 or XFe96 Cell Culture
Microplate and (Agilent Technologies). The results were normalized to protein
concentration or cell number as indicated.
Table 1 Information of patients with diabetes and controls.
Donor Group Gender Age HbA1c
(mmol/mol)
Diagnosis Medication
01 DFU M 66 45 T2DM, DFU, hypertension, renal failure stage 3, TIA Metformin, Insulin Aspart, Insulin Glargine, Atenolol, Lisinopril,
Fluoxacillin
02 DFU F 57 63 T2DM, DFU, osteomyelitis, chronic charcot foot Fluoxacillin, Sitagliptine, Repaglinide, Furosemide, Felodipine,
Enalapril, Atorvastatin, Oxycondone
03 DFU M 60 74 T2DM, DFU, hypertension Metformin, Insulin Aspart, Insulin Glargine, Atenolol, Lisinopril,
Fluoxacillin
04 DFU M 81 45 T2DM, DFU, dyslipidemia, TIA, CAD, CML Insulin Aspart, Insulin Protamine, Acetylsalicylic acid, Imatinib,
Bisoprolol, Furosemide, Fluoxacillin
05 DFU M 70 51 T2DM, DFU, renal failure stage 3 Insulin Glargine
06 DFU M 69 T2DM, DFU, hypertension, dyslipidemia Insulin Glargine, Metformin
07 DFU M 86 61 T2DM, DFU, hypertension, dyslipidemia, atrial
fibrillation, TIA, CHF, Charcot foot
Insulin Aspart, Insulin Protamine
08 DFU M 64 79 T2DM, DFU, hypertension, dyslipidemia, renal failure
stage 3, COPD
Insulin Glargine, Insulin Aspart, Acetylsalicylic acid, Furosemid,
Metoprolol, Enalapril, Simvastatin, Ciprofloxacin
VU1 VU M 86 — VU, prostate cancer, depression, cardiac insufficiency,
polycythemia vera
Omeprazole, calcium carbonate, and cholecalciferol, Furix,
Metoprolol, Losartan, Oxycodone, Paracetamol, Zopiclone,
Mirtazapine, Warfarin, Prednisolone, Lactulose, Enanton Depot
VU2 VU F 78 — VU, atherosclerosis in extremity arteries Trombyl, Simvastatin, Oxycodone, Clopidrogel
VU3 VU F 71 — VU, atrial fibrillation, venous thrombosis Calcium carbonate, Potassium chloride, Fragmin, Iron sulfate,
Bisoprolol
VU4 VU F 77 — VU, skin defect after surgery Prednisolon, Paracetamol, Tramadol, Calcium carbonate, losartan,
Etarnecept
VU5 VU F 87 — VU, varices, peripheral atherosclerosis Natrium chloride, Paracetamol
VU6 VU M 69 — Split skin graft
VU7 VU F 81 —
T2DM type 2 diabetes, DFU diabetes foot ulcer, VU venous ulcer, TIA transcient ischemic attack, CVD cardiovascular disease, COPD chronic obstructive pulmonary disease.
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Electron paramagnetic resonance (EPR) spectroscopy. ROS levels were mea-
sured using cyclichydroxylamine (CMH) spin probe and a CP radical standard
curve, using EPR spectrometer (Noxygen, Elzach, Germany). HDF cells were
transfected with miR-210 mimic/control mimic and were treated with normal or
high glucose and hypoxia or normoxia 16 h after transfection. Following 24 h of
treatment, media was removed and the cells were washed twice with PBS. Seven
hundred microliters CMH buffer (200 μM) was added to the cells and were
incubated in a cell incubator for 30 min. The cells were collected in CMH buffer
and were frozen in liquid nitrogen prior to measurement.
Statistics and reproducibility. Statistical analysis and graphing were performed
using GraphPad Prism software (version 6). Outliers were identified using Grubbs’
test. Normality of distribution was analyzed using the Kolmogorov–Smirnov test.
Differences between two groups were analyzed using two-sided Student’s t test for
data with normal distribution, and nonparametric test was used for data that was
not normally distributed. Multiple comparisons of three or more groups were
performed using one-way ANOVA or two-way ANOVA followed by Bonferroni’s
post hoc test. P < 0.05 was considered statistically significant. All measures were
taken from distinct samples, and the sample sizes are presented in figure legends.
All the in vitro experiments were performed at least three times independently.
Data are presented as mean ± standard error of the mean (s.e.m.).
Study approval. The experimental animal procedure was approved by the North
Stockholm Ethical Committee for the Care and Use of Laboratory Animals. The
study using human material was reviewed and approved by the Regional Ethical
Committee of Stockholm. Written informed consent was received from partici-
pants prior to inclusion in the study. The study was conducted according to the
Declaration of Helsinki’s principles.
Data availability
The datasets generated during and/or analyzed during the current study are available
from the corresponding authors on reasonable request.
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